JMJD2D CRISPR Activation Plasmid (h): sc-404743-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- JMJD2D CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- JMJD2D CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by JMJD2D CRISPR Activation Plasmid (h) and JMJD2D CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the KDM4D transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JMJD2D CRISPR Activation Plasmid (h) | sc-404743-ACT | 20 µg | $397.00 |
Human KDM4D encodes the histone lysine demethylase JMJD2D, a Jumonji C (JmjC) domain enzyme that removes repressive methyl marks on histone H3, particularly H3K9me3/me2. By remodeling chromatin accessibility, JMJD2D influences transcriptional programs linked to DNA damage responses, cell-cycle control, and lineage-specific gene regulation. KDM4D activity intersects with epigenetic and signaling networks that govern genome stability and transcriptional plasticity, processes frequently perturbed in cancer and other disorders featuring dysregulated chromatin states. As a chromatin-modifying factor, JMJD2D is widely studied for its role in modulating enhancer and promoter activity and coordinating context-dependent gene expression.
JMJD2D CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous KDM4D expression without altering the underlying DNA sequence.
JMJD2D CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the KDM4D locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the KDM4D transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous JMJD2D expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native KDM4D locus and enabling the study of JMJD2D-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of JMJD2D pathway restoration in tumor cells with silenced or reduced KDM4D expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.